HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer

Haifeng Zhu, Zuzana Berkova, Rohit Mathur, Lalit Sehgal, Tamer Khashab, Rong-Hua Tao, Xue Ao, Lei Feng, Anita L. Sabichi, Boris Blechacz, Asif Rashid, and Felipe Samaniego

Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies

Jerome T. Higgs, John S. Jarboe, Joo Hyoung Lee, Diptiman Chanda, Carnellia M. Lee, Champion Deivanayagam, and Selvarangan Ponnazhagan

The lncRNA DRAIC/PCAT29 Locus Constitutes a Tumor-Suppressive Nexus

Kouhei Sakurai, Brian J. Reon, Jordan Anaya, and Anindya Dutta

LncRNA Expression Discriminates Karyotype and Predicts Survival in B-Lymphoblastic Leukemia

Thilini R. Fernando, Norma J. Rodriguez Malave, Ella V. Waters, Weihong Yan, David Casero, Giuseppe Basso, Martina Pigazzi, and Dinesh S. Rao

Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins

Uday Bhanu Maachani, Tamalee Kramp, Ryan Hanson, Shuping Zhao, Orieta Celiku, Uma Shankavaram, Riccardo Colombo, Natasha J. Caplen, Kevin Camphausen, and Anita Tandle

Detection of Tumor Suppressor Genes in Cancer Development by a Novel shRNA-Based Method

Johannes von Burstin, Sandra Diersch, Günter Schneider, Maximilian Reichert, Anil K. Rustgi, and Roland M. Schmid

Genome-Wide Profiling of TRACK Kidneys Shows Similarity to the Human ccRCC Transcriptome

Leiping Fu, Denise R. Minton, Tuo Zhang, David M. Nanus, and Lorraine J. Gudas

Tumor Suppressor NF2 Blocks Cellular Migration by Inhibiting Ectodomain Cleavage of CD44

Monika Hartmann, Liseth M. Parra, Anne Ruschel, Sandra Böhme, Yong Li, Helen Morrison, Andreas Herrlich, and Peter Herrlich

Breast Cancer–Specific miR Signature Unique to Extracellular Vesicles Includes "microRNA-like" tRNA Fragments

Nicole Guzman, Kitty Agarwal, Dilip Asthagiri, Lianbo Yu, Motoyasu Saji, Matthew D. Ringel, and Michael E. Paulaitis

The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells

Perla El-Hage, Ambre Petitalot, Anne-Hélène Monsoro-Burq, Frédérique Maczkowiak, Keltouma Driouch, Etienne Formstecher, Jacques Camonis, Michele Sabbah, Ivan Bieche, Rosette Lidereau, and François Lallemand

The Tumor Suppressor NKX3.1 Is Targeted for Degradation by DYRK1B Kinase

Liang-Nian Song, Jose Silva, Antonius Koller, Andrew Rosenthal, Emily L. Chen, and Edward P. Gelmann
SIGNAL TRANSDUCTION

923 mTOR/ MYC Axis Regulates O-GlcNAc Transferase Expression and O-GlcNAcylation in Breast Cancer
Valerie L. Sodi, Sakina Khaku, Raisa Krutilina, Luciana P. Schwab, David J. Vocadlo, Tiffany N. Seagroves, and Mauricio J. Reginato

934 MAPK7 Regulates EMT Features and Modulates the Generation of CTCs
Sarah Javaid, Jianmin Zhang, Gromoslaw A. Smolen, Min Yu, Ben S. Wittner, Anurag Singh, Kshitij S. Arora, Marissa W. Madden, Rushil Desai, Matthew J. Zubrowski, Benjamin J. Schott, David T. Ting, Shannon L. Stott, Mehmet Toner, Shyamala Maheswaran, Toshi Shioda, Sridhar Ramaswamy, and Daniel A. Haber

ABOUT THE COVER

Epithelial-to-mesenchymal transition (EMT) has been implicated in tumor cell migration, invasion, and metastasis. Suppression of MAPK7 increases E-cadherin (CDH1) expression, inhibits cell migration, and reduces circulating tumor cells and the appearance of lung metastases. The cover shows immunofluorescent staining of A549 cancer cells following knockdown of MAPK7, showing increased expression of CDH1 localized to the cell membrane (CDH1, green, Vimentin, red, DAPI, blue). Please see the article by Javaid and colleagues (beginning on page 934) for more information.